Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.522
Bid: 1.50
Ask: 1.58
Change: 0.015 (0.98%)
Spread: 0.08 (5.333%)
Open: 1.50
High: 1.536
Low: 1.47
Prev. Close: 1.525
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

13 Apr 2017 15:30

RNS Number : 4428C
Silver Falcon PLC
13 April 2017
 

13 April 2017

Silver Falcon Plc

("Silver Falcon" or the "Company")

 

Final Results for the year ended 31 December 2016

 

Silver Falcon plc (LSE: SILF), a business formed for the purpose of acquiring another business or asset, reports its Final Results for the year ended 31 December 2016.

 

All financial amounts are stated in GBP British pounds unless otherwise indicated.

 

Chairman's Statement

 

I hereby present the annual accounts for the year ended 31st December 2016. During the year the Company reported a loss of £519,898 (31 December 2015 - loss of £80,367) which arose predominantly from professional fees in connection with the due diligence and legal documentation relating to potential transactions, in particular with the current transaction under review. As at the date of this report the Company has approximately £1m of cash balances.

 

Following its listing on the London Stock Exchange on 9th November 2015, the Company has focused on the evaluation of various acquisition opportunities. To that end, it announced on 30th December 2015 that it had entered into a non-binding Memorandum of Understanding with the board and principal shareholder in Lime Holdings Limited ("Lime") regarding a possible acquisition of 100% of the share capital of Lime by way of a share for share exchange. On 30th September 2016 the Company announced that it was no longer proceeding with that transaction following detailed due diligence.

 

As at the year ended 31 December 2016, the Company was in talks with another potential business with an eventual acquisition expected to finalise before the end of the second quarter 2017. As at the date of this report, this is still the case and the transaction is at an advanced stage and, whilst no binding agreement has yet been entered into the directors are optimistic of a successful outcome.

 

I would like to thank all those who have assisted in relation to the possible acquisitions reviewed and remain hopeful of a successful future.

 

 

 

 

Geoffrey Dart

 

Executive Chairman

 

 

 

 

For further information please contact:

 

Timothy Le Druillenec

Tel: 07874 762 821

 

Statement of Comprehensive Income

 

 

 

Year ended

31 December 2016

Period ended 

31 December 2015

 

Note

£

£

Continuing operations

 

 

 

 

 

 

 

Revenue

 

-

-

Administrative expenses

3

(519,898)

(46,027)

listing costs

 

-

(34,340)

 

 

 

 

Operating loss

 

(519,898)

(80,367)

 

 

 

 

 

Loss before taxation

 

 

 

(519,898)

 

(80,367)

 

 

 

 

Taxation

4

-

-

 

Loss for the year attributable to equity owners

 

 

(519,898)

 

(80,367)

 

 

 

 

Other comprehensive income for the year

 

-

-

Total comprehensive income for the year attributable to the equity owners

 

 

 

(519,898)

 

 

(80,367)

 

 

 

 

Earnings/(loss) per share attributable to equity owners

 

 

 

 

Basic and diluted (£ per share)

 

5

 

(0.008)

 

(0.005)

 

The notes to the financial statements form an integral part of these financial statements.

 

 

Statement of Financial Position

 

 

 

 

As at

31 December 2016

As at

31 December 2015

Note

£

£

Assets

 

 

Current assets

 

 

Trade and other receivables

6

1,680

31,167

Cash and cash equivalents

7

1,045,723

1,323,869

 

 

 

Total current assets

1,047,403

1,355,036

Total assets

1,047,403

1,355,036

 

 

 

Equity and liabilities

 

 

Equity attributable to shareholders

 

 

Called up share capital

Share Premium

8

9

669,000

841,243

649,000

781,243

Retained earnings

(606,535)

(86,637)

 

 

 

Total equity

903,708

1,343,606

 

 

 

Liabilities

 

 

Current liabilities

 

 

Trade and other payables

10

143,695

11,430

 

 

 

Total liabilities

143,695

11,430

 

 

 

Total equity and liabilities

1,047,403

1,355,036

 

The notes to the financial statements form an integral part of these financial statements.

 

 

 

 

 

 

Company Registration Number: 08401609

 

Statement of Changes in Equity

 

 

Called up share

capital

Share Premium

Retained earnings

Total

CURRENT YEAR

£

£

£

£

 

 

 

 

 

Brought forward at 1 January 2016

649,000

781,243

(86,637)

1,343,606

Loss in year

Other Comprehensive Income

-

-

-

-

(519,898)

-

(519,898)

-

 

 

 

 

 

Total comprehensive income for the year

 

-

 

-

 

(519,898)

 

(519,898)

Issue of share capital net of share issue costs

 

20,000

 

60,000

 

-

 

80,000

 

 

 

 

 

As at 31 December 2016

669,000

841,243

(606,535)

903,708

 

 

Called up share

capital

Share Premium

Retained earnings

Total

 

£

£

£

£

 

 

 

 

 

As at 1 March 2015

50,000

-

(6,270)

43,730

 

 

 

 

 

Loss in period

Other Comprehensive Income

-

-

-

-

(80,367)

-

(80,367)

-

 

 

 

 

 

Total comprehensive income for the period

 

-

 

-

 

(80,367)

 

(80,367)

 

 

 

 

 

Issue of share capital net of share issue costs

599,000

 

781,243

 

-

 

1,380,243

 

 

 

 

 

As at 31 December 2015

649,000

781,243

(86,637)

1,343,606

 

Share capital comprises the ordinary issued share capital of the Company.

 

Share Premium represents consideration less nominal value of issued shares and costs directly attributable to the issue of new shares.

 

Retained earnings represent the cumulative retained losses of the Company at the reporting date.

 

 

 

The notes to the financial statements form an integral part of these financial statements.

 

Statement of Cash Flows

 

 

 

Year ended

31 December 2016

Period ended 31 December 2015

 

Note

£

£

Cash flow from operating activities

 

 

 

Loss before taxation

Adjustments for:

Share-based payment

 

(519,898)

 

80,000

(80,367)

 

-

 

 

 

 

Changes in working capital

 

 

 

(Increase)/decrease in trade and other receivables

 

29,487

6,333

Increase in trade and other payables

 

132,265

11,430

 

 

 

 

Net cash used in operating activities

 

(278,146)

(62,604)

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

Proceeds from issuance of shares net of issue costs

 

-

1,380,243

 

 

 

 

Net cash generated from financing activities

 

-

1,380,243

 

 

 

 

Cash flows from investing activities

 

-

-

 

 

 

 

Net cash used in investing activities

 

-

-

 

 

 

 

 

 

 

 

Increase/(decrease) in cash and cash equivalents

 

(278,146)

1,317,639

 

 

 

 

Cash and cash equivalents at beginning of period

 

1,323,869

6,230

 

 

 

 

Cash and cash equivalents at end of period

7

1,045,723

1,323,869

 

Major non-cash transactions

 

On the 11 November 2016 2,000,000 new Ordinary Shares of £0.01 nominal value were issued at a premium of £0.03 per share to M6 Limited as settlement for a fee of £80,000 for online marketing services.

 

 

 

 

 

 

The notes to the financial statements form an integral part of these financial statements.

Notes to the Financial Statements

1. General Information

 

The Company's principal activity is currently that of a 'cash shell' actively seeking an investment. The Company was incorporated in England and Wales on 13 February 2013 as a private limited Company. The Company did not trade during the financial period ended 31 December 2016, the majority of expenses related to legal and professional fees in connection with the aborted acquisition and a new potential acquisition, along with consultancy and legal fees as well as general administration expenses.

 

The Company's registered office is located at 5 Fleet Place, London EC4M 7RD, and is listed on the London Stock Exchange.

 

2. Summary of Significant Accounting Policies

 

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

 

a) Basis of Preparation

 

The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") and IFRS Interpretations Committee (IFRS IC) interpretations as adopted for use by the European Union, and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

 

i) New and amended standards mandatory for the first time for the period beginning 1 January 2016

 

No new standards, amendments or interpretations, effective for the first time for the financial year beginning on or after 1 January 2016 have had a material impact on the Company.

 

ii) New standards, amendments and Interpretations in issue but not yet effective or not yet endorsed and not early adopted

 

The standards and interpretations that are issued, but not yet effective, up to the date of issuance of the financial statements are listed below. The Company intend to adopt these standards, if applicable, when they become effective.

 

Standard

Impact on initial application

Effective date

IAS 7 (Amendments)

Disclosure Initiative

*1 January 2017

IAS 12 (Amendments)

Recognition of Deferred Tax

*1 January 2017

IFRS 9 (Amendments)

Financial Instruments

1 January 2018

IFRS 15

Revenue from contracts with customers

*1 January 2018

IFRS 16

 Leases

*1 January 2019

IFRS 2 (Amendments)

Share-based payments - classification and measurement

*1 January 2018

Annual improvements

2014-2016 Cycle

*1 January 2017/ 1 January 2018

IAS 40 (Amendments)

Transfer of investment property

1 January 2017

IFRIC Interpretations 22

Foreign currency transactions and advanced consideration

1 January 2018

IFRS 4 (Amendments)

Applying IFRS 9 'with IFRS 4' Insurance contracts

*1 January 2018

IFRIC 22

Foreign currency transactions and advance consideration

*1 January 2018

IAS 40 (Amendments)

Transfers of investment properties

*1 January 2018

 

* Subject to EU endorsement

 

The Company is evaluating the impact of the new and amended standards above. The Directors believe that these new and amended standards are not expected to have a material impact on the Company's results or shareholders' funds but this will revisited once an acquisition has been made. However, the following standards should be looked at in more detail:

 

IFRS 9, 'Financial instruments', addresses the classification, measurement and recognition of financial assets and financial liabilities. The complete version of IFRS 9 was issued in July 2014. It replaces the guidance in IAS 39 that relates to the classification and measurement of financial instruments. IFRS 9 retains but simplifies the mixed measurement model and establishes three primary measurement categories for financial assets: amortised cost, fair value through OCI and fair value through P&L. The basis of classification depends on the entity's business model and the contractual cash flow characteristics of the financial asset. Investments in equity instruments are required to be measured at fair value through profit or loss with the irrevocable option at inception to present changes in fair value in OCI not recycling. There is now a new expected credit losses model that replaces the incurred loss impairment model used in IAS 39. For financial liabilities there were no changes to classification and measurement except for the recognition of changes in own credit risk in other comprehensive income, for liabilities designated at fair value through profit or loss.

 

IFRS 9 relaxes the requirements for hedge effectiveness by replacing the bright line hedge effectiveness tests. It requires an economic relationship between the hedged item and hedging instrument and for the 'hedged ratio' to be the same as the one management actually use for risk management purposes. Contemporaneous documentation is still required but is different to that currently prepared under IAS 39. The standard is effective for accounting periods beginning on or after 1 January 2018 but early adoption is permitted.

 

As at the year end, the Company only hold basic financial instruments such as loans and receivables and other liabilities measured at amortised cost. Because of this, the Director's believe the potential changes caused by IFRS 9 will be immaterial until an acquisition of a trading company has taken place.

 

IFRS 15, 'Revenue from contracts with customers' deals with revenue recognition and establishes principles for reporting useful information to users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. Revenue is recognised when a customer obtains control of a good or service and thus has the ability to direct the use and obtain the benefits from the good or service. The standard replaces IAS 18 'Revenue' and IAS 11 'Construction contracts' and related interpretations. The standard is effective for annual periods beginning on or after 1 January 2018 and earlier application is permitted.

 

As at the year-end and at the date of the approval of the financial statements, no revenue has been generated. Revenue will only be generated once an acquisition of a trading company has taken place. Once this is the case, the Company will determine a reasonable time frame for adopting IFRS 15 and the best approach in providing reliable comparative information.

 

b) Significant accounting judgements, estimates and assumptions

 

The preparation of the financial statements in conformity with International Financial Reporting Standards requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies.

 

Estimates and judgements are continually evaluated, and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

 

The principal areas in which judgement is applied are as follows:

 

Going Concern

 

The preparation of financial statements requires an assessment on the validity of the going concern assumption.

 

The Directors have reviewed projections for a period of at least 12 months from the date of approval of the financial statements. The Company has no revenues but significant cash resources were raised following its listing to finance its activities whilst it identifies and completes suitable acquisition opportunities. On 30 September 2016, a potential acquisition of Lime Holdings Limited was halted. Since this time, the Company have been looking at other potential acquisitions but as of yet have not come to a binding agreement.

 

In making their assessment of Going Concern, the Directors acknowledge that the Company has a very small cost base and can therefore confirm that they hold sufficient funds to ensure they can meet their ongoing working capital needs to settle their debts as they fall due for a period of at least one year from date of approval of these financial statements. Accordingly, the Board believes it is appropriate to adopt the going concern basis in the preparation of the financial statements.

 

c) Financial Instruments

 

Financial assets and liabilities are recognised in the Company's statement of financial position when the Company becomes a party to the contractual provisions of the instrument. The Company currently does not use derivative financial instruments to manage or hedge financial exposures or liabilities.

 

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for maturities greater than 12 months after the end of the reporting period. These are classified as non-current assets. The Company's loans and receivables comprise Trade and Other Receivables and Cash and Cash Equivalents in the Statement of Financial Position

 

d) Trade and Other Receivables and Payables

 

Trade and other receivables are amounts due from customers for merchandise sold or services performed in the ordinary course of business. If collection is expected in one year or less (or in the normal operating cycle of the business if longer), they are classified as current assets. If not they are presented as non-current assets.

 

Trade and other receivables are recognised initially at fair value, and subsequently measured at amortised cost using the effective interest method, less provision for impairment.

 

Other liabilities measured at amortised cost are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. The liabilities are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer. If not, they are presented as non-current liabilities.

 

The liabilities are recognised initially at fair value, and subsequently measured at amortised cost using the effective interest method.

 

 

e) De-recognition of Financial Instruments

 

i. Financial Assets

 

A financial asset is derecognised where:

 

· the right to receive cash flows from the asset has expired;

· the Company retains the right to receive cash flows from the asset, but has assumed an obligation to pay them in full without material delay to a third party under a pass-through arrangement; or

· the Company has transferred the rights to receive cash flows from the asset, and either has transferred substantially all the risks and rewards of the asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

 

ii. Financial Liabilities

 

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. Where an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in the statement of comprehensive income.

 

f) Taxation

 

Current Tax

 

Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the tax authorities. The tax rates and the tax laws used to compute the amount are those that are enacted or substantively enacted by the statement of financial position date.

 

Deferred Tax

 

Deferred income tax is recognised on all temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements, with the following exceptions:

 

· where the temporary difference arises from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither accounting nor taxable profit or loss;

· in respect of taxable temporary differences associated with investment in subsidiaries, associates and joint ventures, where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future; and

· deferred income tax assets are recognised only to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, carried forward tax credits or tax losses can be utilised.

 

Deferred income tax assets and liabilities are measured on an undiscounted basis at the tax rates that are expected to apply when the related asset is realised or liability is settled, based on tax rates and laws enacted or substantively enacted at the statement of financial position date.

 

The carrying amount of deferred income tax assets is reviewed at each statement of financial position date. Deferred income tax assets and liabilities are offset, only if a legally enforcement right exists to set off current tax assets against current tax liabilities, the deferred income taxes related to the same taxation authority and that authority permits the Company to make a single net payment.

 

Income tax is charged or credited directly to equity if it relates to items that are credited or charged to equity. Otherwise income tax is recognised in the statement of comprehensive income.

 

g) Segmental Reporting

 

At this point, identifying and assessing investment projects is the only activity the Company is involved in and is therefore considered as the only operating/reportable segment.

 

Therefore the financial information of the single segment is the same as that set out in the Company statement of comprehensive income, Company statement of financial position, the Company statement of changes to equity and the Company statement of cashflows.

 

h) Financial Risk Management Objectives and Policies

 

The Company does not enter into any forward exchange rate contracts.

 

The main financial risks arising from the Company's activities are cash flow interest rate risk, liquidity risk, price risk (fair value) and credit risk. Further details on the risk disclosures can be found in Note 13.

 

i) Equity

 

Equity instruments issued by the Company are recorded net at proceeds after direct issue costs.

 

j) Cash and Cash Equivalents

 

Cash and cash equivalents comprise cash held in bank. This definition is also used for the Statement of Cash Flows.

 

The Company considers the credit ratings of banks in which it holds funds in order to reduce exposure to credit risk. The Company only keeps its holdings of cash and cash equivalents with institutions which have a minimum credit rating of 'A-'.

 

The Company considers that it is not exposed to major concentrations of credit risk.

 

 

3. Expenses by Nature

 

 

Year ended

31 December

2016

Period ended

31 December

2015

 

£

£

Advertising and PR

80,400

17,050

Fees payable to the Company's auditor:

- for the audit of the annual accounts

- non audit services

 

11,575

24,000

 

7,025

-

Legal and professional fees

296,016

6,825

Establishment expenses

107,907

15,127

Total Administrative expenses

519,898

46,027

 

4. Income tax

 

Analysis of charge in the year

 

Year ended

31 December

2016

Period ended

31 December

Restated 2015

 

£

£

Current tax:

UK corporation tax on loss for the year

-

-

Deferred tax

-

-

Tax on loss on ordinary activities

-

-

 

 

 

Loss on ordinary activities before tax

(519,898)

(80,367)

 

 

 

Analysis of charge in the year

 

 

Loss on ordinary activities multiplied by rate of corporation tax in the UK of 20%

(103,980)

(16,073)

 

Disallowed items

Timing differences

54,145

-

3,168

3,700

Tax losses carried forward

(49,835)

(9,205)

Current tax charge

-

-

Effects of:

 

 

Tax Loss brought forward

Prior year adjustment

Tax Loss in period unutilised

(46,027)

(18,498)

(230,673)

-

-

(46,027)

Tax Loss carried forward

(295,198)

(46,027)

Current tax charge for the year as above

-

-

 

The Company has accumulated tax losses arising in the UK of approximately £295,198 (Dec 2015: £46,027) that are available, under current legislation, to be carried forward against future profits. No deferred tax asset has been recognised against these losses.

 

5. Earnings per share

 

The calculation of the Basic and fully diluted earnings per share is calculated by dividing the loss for the year from continuing operations of £519,898 (2015: £80,367) for the Company by the weighted average number of ordinary shares in issue during the year of 65,173,973 (2015: 16,519,016).

 

There are no potential dilutive shares in issue.

 

 

6. Trade and other receivables

 

 

As at

31 December

2016

As at 31 December

2015

 

£

£

VAT receivable

Other receivables

-

180

28,082

335

Prepayments

1,500

2,750

 

1,680

31,167

 

There are no material differences between the fair value of trade and other receivables and their carrying value at the year end.

 

No receivables were past due or impaired at the year end.

 

7. Cash and cash equivalents

 

 

As at

31 December2016

As at 31 December 2015

 

£

£

Cash at bank

1,045,723

1,323,869

 

1,045,723

1,323,869

 

8. Called up share capital

 

On 30 October 2015 and prior to the Company's listing, 21,600,000 new Ordinary Shares of £0.01 nominal value had been issued at par and fully paid. On 9 November 2015 following the Company's listing on the London Stock Exchange, 43,300,000 new Ordinary Shares of £0.01 nominal value were issued, fully paid at a premium of £0.02 per share. On 11th November 2016 2,000,000 new Ordinary Shares of £0.01 nominal value were issued at a premium of £0.03 per share to M6 Limited as settlement for a fee of £80,000 for online marketing services.

 

The ordinary shares have attached to them full voting, dividend and capital distribution rights (including on a winding up). The ordinary shares do not confer any rights of redemption.

 

 

Number of Shares

Ordinary Shares

Share Capital

£

 

 

 

At 1 March 2015

5,000,001

50,000

Subscription 29 July 2015

2,499,999

25,000

Intermediate Placees subscription 30 October 2015

14,100,000

141,000

Placing 9 November 2015

43,300,000

433,000

 

 

 

At 1 January 2016

64,900,000

649,000

Ordinary Shares issued 11 November 2016

2,000,000

20,000

 

 

 

At 31 December 2016

 

 

Ordinary Shares of £0.01

66,900,000

669,000

 

 

 

9. Share Premium

 

Summary of Share Premium

 

 

Share Premium Paid (net of cost of shares)

£

Less share issue costs

£

Net Share Premium

£

At 1 March 2015

-

-

-

Placing 9 November 2015

866,000

(84,757)

781,243

 

 

 

 

At 1 January 2016

866,000

(84,757)

781,243

 

 

 

 

Ordinary Shares issued 11 November 2016

 

60,000

 

-

 

60,000

 

 

 

 

At 31 December 2016

926,000

(84,757)

841,243

 

10. Trade and other payables

 

As at

31 December 2016

As at 31 December 2015

 

£

£

 

 

 

Accruals

143,695

11,430

 

143,695

11,430

 

11. Related party disclosures

 

With effect from 11 November 2015, M6 Limited ("M6") entered into an agreement to provide web development, online marketing, mobile application development and marketing, content production, advertising, public relations, and lead generation services to the Company for a fee of £80,000. The Company has agreed with M6 to issue 2,000,000 Ordinary Shares at the Placing Price at Admission in settlement of monies owed to M6. As at 11 November 2016, 2,000,000 Ordinary Shares were issued to M6 as payment for their services; further details of this transaction are disclosed in note 8. Adrian Beeston, a director of the Company, is also a director of M6 and holds c.17 per cent. of the issued ordinary share capital of M6 Limited.

 

During the year, the Company paid £20,239 (2015: £3,000) to Dukemount Capital Plc in respect of rent. Peter Redmond, a Director of the Company, is also Director of Dukemount Capital Plc. As at the year-end, £Nil (2015: £1,500) was owed to Dukemount in respect of rent.

 

 

 

 

12. Directors' emoluments

 

Details concerning Directors' remuneration can be found below. The Directors are considered to be the key management.

 

Name of Director

Short term employee benefits

Post employment benefits

Other long term benefits

Termination benefits

 

 

 

Other

Total

Geoffrey Dart

-

 

 

 

 

-

Peter Redmond

-

 

 

 

 

-

Adrian Beeston

-

 

 

 

 

-

 

 

 

 

 

 

 

Total

-

-

-

-

-

-

 

Further information concerning Directors' remuneration can be found in the Directors' Remuneration report.

 

13. Financial instruments

 

The following table sets out the categories of financial instruments held by the Company as at the year ended 31 December 2016 and period ended 31 December 2015:

 

2016

Loans and Receivables

Total

 

£

£

Trade and other receivables, except prepayments

Cash and cash equivalents

180

1,045,723

180

1,045,723

 

1,045,903

1,045,903

 

2015

Loans and Receivables

Total

 

£

£

Trade and other receivables, except prepayments

Cash and cash equivalents

28,417

1,323,869

28,417

1,323,869

 

1,352,286

1,352,286

 

2016

Other financial liabilities at amortised cost

Total

 

£

£

Trade and other payables

143,695

143,695

 

143,695

121,695

2015

Other financial liabilities at amortised cost

Total

 

£

£

Trade and other payables

11,430

11,430

 

11,430

11,430

 

 

 

 

 

Cash & cash equivalents

All of the cash balance as per the Statement of Financial Position is held with the following institutions:

 

 

2016

2015

 

£

£

Metro Bank PLC

1,044,502

1,323,869

Royal Bank of Scotland

1,221

-

 

a) Interest rate risk

 

The Company has floating rate financial assets in the form of deposit accounts with major banking institutions; however, it is not currently subjected to any other interest rate risk. 

 

Based on cash balances as above as at the statement of financial position date, a rise in interest rates of 1% would not have a material impact on the profit and loss of the Company and such is not disclosed.

 

In relation to sensitivity analysis, there was no material difference to disclosures made on financial assets and liabilities.

 

b) Liquidity risk

 

The Company regularly reviews its major funding positions to ensure that it has adequate financial resources in meeting its financial obligations. The Company takes liquidity risk into consideration when deciding its sources of funds. The principle liquidity risk facing the business is the risk of going concern which has been discussed in Note 2 (b).

 

c) Credit risk

 

The Company had receivables of £1,680 at 31 December 2016. Company receivables of £1,680 at the year end were not past due, and the Directors consider there to be no credit risk arising from these receivables.

 

d) Capital risk management

 

The Company defines capital as the total equity of the Company. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

 

In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

 

e) Fair value of financial assets and liabilities

 

There are no material differences between the fair value of the Company's financial assets and liabilities and their carrying values in the financial statements.

 

 

 

14. Staff Costs

 

During the year to 31 December 2016 there were no staff costs as no staff were employed by the Company other than the directors. Therefore, the average staff number for the year was 3 in administration, this includes the Directors.

 

15. Ultimate Controlling Party

 

The Directors have determined that there is no controlling party as no individual shareholder holds a controlling interest in the Company.

 

16. Copies of the Annual Report

 

Copies of the annual report will be available on the Company's website at www.silverfalconplc.com and from the Company's registered office, 5 Fleet Place, London EC4M 7RD.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR IJMPTMBBBMFR
Date   Source Headline
25th Apr 20247:00 amRNSFinal Results
28th Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSPlacing to Raise US$4.2 million
16th Feb 20247:00 amRNSCBR Brain Delivery
14th Feb 20247:00 amRNSCBR Intranasal Delivery
9th Feb 20247:00 amRNSFDA Consents to Phase I Trials of HEMO-CAR-T
2nd Feb 20247:00 amRNSApproval and Issuance of U.S. Conditioning Patent
16th Jan 20247:00 amRNSSubmission of Complete Response to Clinical Hold
8th Jan 20247:00 amRNSHEMO-CAR-T Process Qualification Run Completed
28th Nov 202312:19 pmRNSPlacing to Raise £534,375
27th Nov 20237:00 amRNSCBR Expanded to Treatment of Cancer
15th Nov 20237:00 amRNSLentivirus Re-manufacturing Completed
31st Oct 20237:00 amRNSTotal Voting Rights
28th Sep 202312:28 pmRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic Investment from Prevail Partners, LLC
14th Sep 20237:00 amRNSClinical Hold Lift Plan is accepted by FDA
8th Sep 20235:11 pmRNSCBR Patent Application Update
10th Jul 20237:00 amRNSFull FDA Review for HEMO-CAR-T IND
30th Jun 20234:07 pmRNSResult of Annual General Meeting
2nd Jun 20232:01 pmRNSPosting of Annual Report & Notice of AGM
2nd Jun 202311:24 amRNSClinical Hold on IND for HEMO-CAR-T
9th May 20237:00 amRNSSubmission of IND for HEMO-CAR-T
28th Apr 202310:05 amRNSEquity Incentive Pool Increase and Option Grant
28th Apr 20237:00 amRNSFinal Results for the Year Ended 31 December 2022
23rd Mar 20231:32 pmRNSHEMO-CAR-T Analytical Release Tests Completed
28th Feb 20237:00 amRNSTotal Voting Rights
7th Feb 20232:30 pmRNSAdmission of Shares to Official List
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSPlacing to Raise £4,056,250
23rd Jan 20237:00 amRNSHEMO-CAR-T 3rd Process Qualification Run Completed
16th Jan 20234:40 pmRNSSecond Price Monitoring Extn
16th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
12th Jan 20234:40 pmRNSSecond Price Monitoring Extn
12th Jan 20234:35 pmRNSPrice Monitoring Extension
12th Jan 20232:05 pmRNSSecond Price Monitoring Extn
12th Jan 20232:00 pmRNSPrice Monitoring Extension
10th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20239:05 amRNSSecond Price Monitoring Extn
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSSingle CBR Can Treat Multiple Viruses
5th Jan 20234:40 pmRNSSecond Price Monitoring Extn
5th Jan 20234:35 pmRNSPrice Monitoring Extension
5th Jan 202311:05 amRNSSecond Price Monitoring Extn
5th Jan 202311:00 amRNSPrice Monitoring Extension
4th Jan 20237:00 amRNSHEMO-CAR-T Process Qualification Run Completed
12th Dec 20227:00 amRNSHEMO-CAR-T First PQ Run Completed
18th Nov 20223:19 pmRNSHEMO-CAR-T Process Development Runs Completed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.